Denali Therapeutics Inc. (DNLI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '20: 9.4M Q4 '20: 316.8M Q1 '21: 7.9M Q2 '21: 22.9M Q3 '21: 5.3M Q4 '21: 12.5M Q1 '22: 42.1M Q2 '22: 52.5M Q3 '22: 184K Q4 '22: 10.3M Q1 '23: 35.1M Q2 '23: 294.1M Q3 '23: 1.3M Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q2 '25: 0 Q2 '26: 3.6M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

Gross Profit Quarterly

0 1.5M 3M 4.5M Q2 '25: 0 Q2 '26: 3.5M Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -85.6M Q4 '21: -77.1M Q1 '22: -66.5M Q2 '22: -61.4M Q3 '22: -107.5M Q4 '22: -105.3M Q1 '23: -120.8M Q2 '23: 170.5M Q3 '23: -113.8M Q4 '23: -132.6M Q1 '24: -117.7M Q2 '24: -116.6M Q3 '24: -123.2M Q4 '24: -129.8M Q1 '25: -145.6M Q2 '25: -135M Q3 '25: -137.4M Q4 '25: -137.4M Q1 '26: -137.4M Q2 '26: -130.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-140M -70M 0 70M 140M 210M Q3 '21: -84.6M Q4 '21: -75.3M Q1 '22: -65.2M Q2 '22: -58.8M Q3 '22: -103.3M Q4 '22: -98.7M Q1 '23: -109.8M Q2 '23: 183.4M Q3 '23: -99.4M Q4 '23: -119.5M Q1 '24: -101.8M Q2 '24: -99M Q3 '24: -107.2M Q4 '24: -114.8M Q1 '25: -133M Q2 '25: -124.1M Q3 '25: -126.9M Q4 '25: -128.5M Q1 '26: -128.4M Q2 '26: -127.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 35K 70K 105K Q2 '25: 0 Q2 '26: 93K Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -41.4M Q4 '21: -65.5M Q1 '22: -72.1M Q2 '22: -42.9M Q3 '22: -57M Q4 '22: -72.7M Q1 '23: -58.8M Q2 '23: -113.2M Q3 '23: -87.4M Q4 '23: -98.7M Q1 '24: -113.6M Q2 '24: -91.2M Q3 '24: -59.1M Q4 '24: -83.7M Q1 '25: -131.5M Q2 '25: -75.3M Q3 '25: -107.3M Q4 '25: -98.5M Q1 '26: -131.2M Q2 '26: -97M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -43.3M Q4 '21: -68.5M Q1 '22: -76.2M Q2 '22: -45.8M Q3 '22: -63.1M Q4 '22: -77.5M Q1 '23: -61.6M Q2 '23: -119M Q3 '23: -89.4M Q4 '23: -100.9M Q1 '24: -115.8M Q2 '24: -96M Q3 '24: -63M Q4 '24: -88.8M Q1 '25: -136.5M Q2 '25: -79.6M Q3 '25: -108.7M Q4 '25: -100.1M Q1 '26: -133.7M Q2 '26: -97.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '20: 102.4M Q2 '20: 105.7M Q3 '20: 107.5M Q1 '21: 120.9M Q2 '21: 121.3M Q3 '21: 121.7M Q1 '22: 122.7M Q2 '22: 123M Q3 '22: 123.5M Q1 '23: 136.5M Q2 '23: 140.9M Q3 '23: 137.6M Q1 '24: 149.4M Q2 '24: 168.8M Q3 '24: 169.5M Q1 '25: 171.2M Q2 '25: 171.4M Q3 '25: 172.4M Q1 '26: 186.6M Q2 '26: 187.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -2.21 Q4 '21: -2.39 Q1 '22: -2.34 Q2 '22: -2.32 Q3 '22: -2.47 Q4 '22: -2.60 Q1 '23: -2.87 Q2 '23: -1.09 Q3 '23: -0.97 Q4 '23: -1.09 Q1 '24: -0.97 Q2 '24: -2.86 Q3 '24: -2.77 Q4 '24: -2.58 Q1 '25: -2.68 Q2 '25: -2.81 Q3 '25: -2.92 Q4 '25: -2.97 Q1 '26: -2.88 Q2 '26: -2.84 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.